Market Research Reports and Industry Reports

Liquid Biopsy Market by Cancer Type (Lung, Breast, Colorectal, Prostate, Liver), Circulating Biomarkers (Circulating Tumor Cells, Circulating Tumor DNA), Product (Instruments, Software), End User (Reference Laboratory, Research Centers) - Forecast to 2021

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • PURCHASE BY
    SECTION

Growing Funding for Research on Liquid Biopsy and Technological Advancements to Boost the Growth of the Liquid Biopsy Market

The liquid biopsy market is expected to reach USD 1.66 billion by 2021 from USD 0.58 billion in 2016, growing at a CAGR of 23.4% during the forecast period of 2016 to 2021. Liquid biopsy is a non-invasive alternative to invasive solid tumor biopsies; it detects biomarkers from primary tumors and from metastatic sites to ascertain genetic information about tumors.

This report segments the liquid biopsy market on the basis of cancer type, circulating biomarkers, end users, products & services, and regions.

Based on cancer type, the market is segmented into lung cancer, breast cancer, colorectal cancer, prostate cancer, liver cancer, and other cancers (melanoma, bladder cancer, and ovarian cancer). Based on circulating biomarkers, the liquid biopsy market is segmented into circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), extracellular vesicles (EVs), and other biomarkers (circulating RNA and protein). The circulating tumor cells segment is expected to account for the largest share of the global liquid biopsy market in 2016, followed by the circulating tumor DNA segment.

Based on end user, the liquid biopsy market is classified into hospital/physician laboratories, reference laboratories, academic and research centers and other end users. The other end-users segment includes public health laboratories, pathology laboratories, and small molecular laboratories. Similarly, based on products and services, the liquid biopsy market is segmented into instruments, reagents, and services and software.

A number of factors, such as technological advancements, increasing number of new cancer cases, benefits of liquid biopsy over solid tumor biopsy, availability of funding, and growing awareness about liquid biopsy through conferences and government initiatives are driving the growth of the liquid biopsy market. However, the unclear regulatory and reimbursement scenario is one of the major factors restraining the growth of this market.

Biocept Inc. (U.S.), Myriad Genetics (U.S.), QIAGEN (Netherlands), Roche (Switzerland), Bio-Rad Laboratories Inc. (U.S.), Trovagene Inc. (U.S.), Guardant Health, Inc. (U.S.), Janssen Diagnostics, LLC (U.S.), Fraunhofer-Gesellschaft (Germany), and MDxHealth SA (U.S.) are the major players in the liquid biopsy market.

Reasons to buy this report:

From an insight perspective, this research report focuses on various levels of analysis—industry analysis (industry trends) and company profiles, which together comprise and discuss the basic views on the competitive landscape; emerging and high-growth segments of the liquid biopsy market; high-growth regions; and market drivers, restraints, and opportunities.

The report provides insights on the following pointers:
 
• Market Penetration: Comprehensive information on products offered by the top players in the global liquid biopsy market

• Product Development/Innovation: Detailed insights on the upcoming technologies, research & development activities, and new product launches in the liquid biopsy market

• Market Development: Comprehensive information about lucrative emerging markets—the report analyzes the markets for liquid biopsy across various regions

• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the global liquid biopsy market

• Competitive Assessment: In-depth assessment of market shares, strategies, products, and manufacturing capabilities of the leading players in the liquid biopsy market.

1 INTRODUCTION 15
1.1 OBJECTIVES OF THE STUDY 15
1.2 MARKET DEFINITION 15
1.3 MARKETS SCOPE 16
1.3.1 MARKETS COVERED 16
1.3.2 YEARS CONSIDERED FOR THE STUDY 17
1.4 CURRENCY 17
1.5 LIMITATIONS 17
1.6 STAKEHOLDERS 17
2 RESEARCH METHODOLOGY 18
2.1 MARKET SIZE ESTIMATION 20
2.2 MARKET BREAKDOWN AND DATA TRIANGULATION 23
2.2.1 KEY DATA FROM SECONDARY SOURCES 24
2.2.2 KEY DATA FROM PRIMARY SOURCES 24
2.2.3 ASSUMPTIONS FOR THE STUDY 25
3.1 INTRODUCTION 26
3.2 CURRENT SCENARIO 26
3.3 FUTURE OUTLOOK 27
3.4 CONCLUSION 30
4 PREMIUM INSIGHTS 31
4.1 LIQUID BIOPSY: MARKET OVERVIEW 31
4.2 GEOGRAPHIC ANALYSIS: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER 32
4.3 LIQUID BIOPSY MARKET SIZE, BY END USER, 2016 VS. 2021 33
4.4 LIQUID BIOPSY MARKET SIZE, BY PRODUCT, 2016 VS. 2021 33
4.5 LIQUID BIOPSY MARKET SIZE, BY CIRCULATING BIOMARKER, 2016 VS. 2021 34
4.6 GEOGRAPHICAL SNAPSHOT OF THE LIQUID BIOPSY MARKET 35
5 MARKET OVERVIEW 36
5.1 INTRODUCTION 37
5.2 MARKET DYNAMICS 37
5.2.1 MARKET DRIVERS 38
5.2.1.1 Increasing number of new cancer cases 38
5.2.1.2 Benefits of liquid biopsy over surgical biopsy 39
5.2.1.3 Technological advancements to boost market growth 40
5.2.1.4 Availability of funding for liquid biopsy research 41
5.2.1.5 Initiatives to increase awareness on liquid biopsy 42
5.2.2 MARKET RESTRAINTS 42
5.2.2.1 Low Sensitivity and specificity 42
5.2.3 MARKET OPPORTUNITIES 43
5.2.3.1 Focus on inorganic strategies 43
5.2.4 MARKET CHALLENGES 44
5.2.4.1 Unclear Regulatory and reimbursement scenario 44
6 INDUSTRY INSIGHTS 45
6.1 INTRODUCTION 45
6.2 REGULATORY APPROVAL PROCESS 45
6.3 MAJOR ONGOING CLINICAL TRIALS IN THE LIQUID BIOPSY MARKET 47
6.4 MAJOR FUNDING ACTIVITIES IN THE LIQUID BIOPSY MARKET 51
7 LIQUID BIOPSY MARKET, BY CANCER TYPE 54
7.1 INTRODUCTION 55
7.1.1 LUNG CANCER 57
7.2 BREAST CANCER 59
7.2.1 COLORECTAL CANCER 61
7.2.2 PROSTATE CANCER 63
7.2.3 LIVER CANCER 65
7.2.4 OTHER CANCERS 66
8 LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER 69
8.1 INTRODUCTION 70
8.2 CIRCULATING TUMOR CELLS 71
8.3 EXTRACELLULAR VESICLES 73
8.4 CIRCULATING TUMOR DNA (CTDNA) 75
8.5 OTHER BIOMARKERS 77
9 LIQUID BIOPSY MARKET, BY PRODUCTS AND SERVICES 79
9.1 INTRODUCTION 80
9.1.1 REAGENTS 81
9.2 INSTRUMENTS 83
9.2.1 SERVICES & SOFTWARE 85
10 LIQUID BIOPSY MARKET, BY END USER 87
10.1 INTRODUCTION 88
10.2 REFERENCE LABORATORIES 89
10.2.1 HOSPITALS AND PHYSICIAN LABORATORIES 90
10.2.2 ACADEMIC AND RESEARCH CENTERS 92
10.2.3 OTHER END USERS 93
11 LIQUID BIOPSY MARKET, BY REGION 95
11.1 INTRODUCTION 96
11.2 NORTH AMERICA 97
11.2.1 U.S. 101
11.2.2 CANADA 105
11.3 EUROPE 108
11.4 ASIA-PACIFIC 113
11.5 REST OF THE WORLD (ROW) 118
12 COMPETITIVE LANDSCAPE 121
12.1 OVERVIEW 122
12.2 COMPETITIVE SITUATION AND TRENDS 123
12.2.1 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS 124
12.2.2 NEW PRODUCT LAUNCHES 125
12.2.3 ACQUISITIONS 126
12.2.4 OTHER DEVELOPMENTS 127
13 COMPANY PROFILES 128

(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*
13.1 INTRODUCTION 128
13.2 BIOCEPT, INC. 129
13.3 QIAGEN 132
13.4 F. HOFFMANN-LA ROCHE AG 135
13.5 BIO-RAD LABORATORIES INC. 137
13.6 MYRIAD GENETICS 139
13.7 JANSSEN DIAGNOSTICS, LLC. 142
13.8 TR0VAGENE INC. 144
13.9 GUARDANT HEALTH INC. 146
13.10 FRAUNHOFER-GESELLSCHAFT 147
13.11 MDX HEALTH SA 148

*Details on MarketsandMarkets view, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments might not be captured in case of unlisted companies.

14 APPENDIX 150
14.1 INSIGHTS OF INDUSTRY EXPERTS 150
14.2 DISCUSSION GUIDE 151
14.3 OTHER DEVELOPMENTS 154
14.4 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 156
14.5 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 158
14.6 AVAILABLE CUSTOMIZATIONS 159
14.7 RELATED REPORTS 160
"


List Of Tables

 TABLE 1 LIQUID BIOPSY PRODUCTS LAUNCHED IN RECENT YEARS 40
 TABLE 2 FUNDS PROVIDED FOR LIQUID BIOPSY, 2013-2016 41
 TABLE 3 CONFERENCES AND AWARENESS PROGRAMS ON LIQUID BIOPSY 42
 TABLE 4 LIQUID BIOPSY MARKET: INORGANIC STRATEGIES (2015-16) 44
 TABLE 5 LIQUID BIOPSY CLINICAL TRIALS 47
 TABLE 6 FUNDING IN LIQUID BIOPSY MARKET 51
 TABLE 7 LIQUID BIOPSY MARKET SIZE, BY CANCER TYPE, 2014–2021 (USD MILLION) 57
 TABLE 8 GLOBAL LIQUID BIOPSY MARKET SIZE FOR LUNG CANCER, BY REGION,
 2014–2021 (USD MILLION) 58
 TABLE 9 NORTH AMERICA: LIQUID BIOPSY MARKET SIZE FOR LUNG CANCER, BY COUNTRY, 2014–2021 (USD MILLION) 59
 TABLE 10 IMPACT OF AGING ON BREAST CANCER DEVELOPMENT 59
 TABLE 11 GLOBAL LIQUID BIOPSY MARKET SIZE FOR BREAST CANCER, BY REGION,
 2014–2021 (USD MILLION) 60
 TABLE 12 NORTH AMERICA: LIQUID BIOPSY MARKET SIZE FOR BREAST CANCER,
 BY COUNTRY, 2014–2021 (USD MILLION) 61
 TABLE 13 GLOBAL LIQUID BIOPSY MARKET SIZE FOR COLORECTAL CANCER, BY REGION, 2014–2021 (USD MILLION) 62
 TABLE 14 NORTH AMERICA: LIQUID BIOPSY MARKET SIZE FOR COLORECTAL CANCER,
 BY COUNTRY, 2014–2021 (USD MILLION) 63
 TABLE 15 GLOBAL LIQUID BIOPSY MARKET SIZE FOR PROSTATE CANCER, BY REGION,
 2014–2021 (USD MILLION) 64
 TABLE 16 NORTH AMERICA: LIQUID BIOPSY MARKET SIZE FOR PROSTATE CANCER,
 BY COUNTRY, 2014–2021 (USD MILLION) 64
 TABLE 17 GLOBAL LIQUID BIOPSY MARKET SIZE FOR LIVER CANCER, BY REGION,
 2014–2021 (USD MILLION) 65
 TABLE 18 NORTH AMERICA: LIQUID BIOPSY MARKET SIZE FOR LIVER CANCER,
 BY COUNTRY, 2014–2021 (USD MILLION) 66
 TABLE 19 GLOBAL LIQUID BIOPSY MARKET SIZE FOR OTHER CANCERS, BY REGION,
 2014–2021 (USD MILLION) 67
 TABLE 20 NORTH AMERICA: LIQUID BIOPSY MARKET SIZE FOR OTHER CANCERS,
 BY COUNTRY, 2014–2021 (USD MILLION) 68
 TABLE 21 LIQUID BIOPSY MARKET SIZE, BY CIRCULATING BIOMARKER,
 2014–2021 (USD MILLION) 70
 TABLE 22 LIQUID BIOPSY MARKET SIZE FOR CIRCULATING TUMOR CELLS, BY REGION, 2014–2021 (USD MILLION) 72
 TABLE 23 NORTH AMERICA: LIQUID BIOPSY MARKET SIZE FOR CIRCULATING TUMOR CELLS, BY COUNTRY, 2014–2021 (USD MILLION) 72
 TABLE 24 LIQUID BIOPSY MARKET SIZE FOR EXTRACELLULAR VESICLES, BY REGION,
 2014–2021 (USD MILLION) 74
 TABLE 25 NORTH AMERICA: LIQUID BIOPSY MARKET SIZE FOR EXTRACELLULAR VESICLES, BY COUNTRY, 2014–2021 (USD MILLION) 74
 TABLE 26 LIQUID BIOPSY MARKET SIZE FOR CIRCULATING TUMOR DNA, BY REGION,
 2014–2021 (USD MILLION) 76
 TABLE 27 NORTH AMERICA: LIQUID BIOPSY MARKET SIZE FOR CIRCULATING TUMOR DNA,
 BY COUNTRY, 2014–2021 (USD MILLION) 76
 TABLE 28 LIQUID BIOPSY MARKET SIZE FOR OTHER BIOMARKERS, BY REGION,
 2014–2021 (USD MILLION) 77
 TABLE 29 NORTH AMERICA: LIQUID BIOPSY MARKET SIZE FOR OTHER BIOMARKERS,
 BY COUNTRY, 2014–2021 (USD MILLION) 78
 TABLE 30 GLOBAL LIQUID BIOPSY MARKET SIZE, BY PRODUCTS & SERVICES,
 2014–2021 (USD MILLION) 81
 TABLE 31 GLOBAL LIQUID BIOPSY REAGENTS MARKET SIZE, BY REGION,
 2014–2021 (USD MILLION) 82
 TABLE 32 NORTH AMERICA: LIQUID BIOPSY REAGENTS MARKET SIZE, BY COUNTRY,
 2014–2021 (USD MILLION) 82
 TABLE 33 GLOBAL LIQUID BIOPSY INSTRUMENTS MARKET SIZE, BY REGION,
 2014–2021 (USD MILLION) 84
 TABLE 34 NORTH AMERICA: LIQUID BIOPSY INSTRUMENTS MARKET SIZE, BY COUNTRY, 2014–2021 (USD MILLION) 84
 TABLE 35 GLOBAL LIQUID BIOPSY SERVICES & SOFTWARE MARKET SIZE, BY REGION,
 2014–2021 (USD MILLION) 85
 TABLE 36 NORTH AMERICA: LIQUID BIOPSY SERVICES & SOFTWARE MARKET SIZE,
 BY COUNTRY, 2014–2021 (USD MILLION) 86
 TABLE 37 LIQUID BIOPSY MARKET SIZE, BY END USER, 2014–2021 (USD MILLION) 88
 TABLE 38 LIQUID BIOPSY MARKET SIZE FOR REFERENCE LABORATORIES, BY REGION, 2014–2021 (USD MILLION) 89
 TABLE 39 NORTH AMERICA: LIQUID BIOPSY MARKET SIZE FOR REFERENCE LABORATORIES, BY COUNTRY, 2014–2021 (USD MILLION) 90
 TABLE 40 LIQUID BIOPSY MARKET SIZE FOR HOSPITALS AND PHYSICIAN LABORATORIES,
 BY REGION, 2014–2021 (USD MILLION) 91
 TABLE 41 NORTH AMERICA: LIQUID BIOPSY MARKET SIZE FOR HOSPITALS AND PHYSICIAN LABORATORIES, BY COUNTRY, 2014–2021 (USD MILLION) 91
 TABLE 42 LIQUID BIOPSY MARKET SIZE FOR ACADEMIC AND RESEARCH CENTERS,
 BY REGION, 2014–2021 (USD MILLION) 92
 TABLE 43 NORTH AMERICA: LIQUID BIOPSY MARKET SIZE FOR ACADEMIC AND RESEARCH CENTERS, BY COUNTRY, 2014–2021 (USD MILLION) 93
 TABLE 44 LIQUID BIOPSY MARKET SIZE FOR OTHER END USERS, BY REGION,
 2014–2021 (USD MILLION) 94
 TABLE 45 NORTH AMERICA: LIQUID BIOPSY MARKET SIZE FOR OTHER END USERS,
 BY COUNTRY, 2014–2021 (USD MILLION) 94
 TABLE 46 LIQUID BIOPSY MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 96
 TABLE 47 NORTH AMERICA: LIQUID BIOPSY MARKET SIZE, BY COUNTRY,
 2014–2021 (USD MILLION) 98
 TABLE 48 NORTH AMERICA: LIQUID BIOPSY MARKET SIZE, BY TYPE OF CANCER,
 2014–2021 (USD MILLION) 99
 TABLE 49 NORTH AMERICA: LIQUID BIOPSY MARKET SIZE, BY PRODUCT,
 2014–2021 (USD MILLION) 99
 TABLE 50 NORTH AMERICA: LIQUID BIOPSY MARKET SIZE, BY CIRCULATING BIOMARKER, 2014–2021 (USD MILLION) 100
 TABLE 51 NORTH AMERICA: LIQUID BIOPSY MARKET SIZE, BY END USER,
 2014–2021 (USD MILLION) 101
 TABLE 52 U.S.: LIQUID BIOPSY MARKET SIZE, BY TYPE OF CANCER,
 2014–2021 (USD MILLION) 102
 TABLE 53 U.S.: LIQUID BIOPSY MARKET SIZE, BY PRODUCT, 2014–2021 (USD MILLION) 103
 TABLE 54 U.S.: LIQUID BIOPSY MARKET SIZE, BY CIRCULATING BIOMARKER,
 2014–2021 (USD MILLION) 103
 TABLE 55 U.S.: LIQUID BIOPSY MARKET SIZE, BY END USER, 2014–2021 (USD MILLION) 104
 TABLE 56 CANADA: LIQUID BIOPSY MARKET SIZE, BY TYPE OF CANCER,
 2014–2021 (USD MILLION) 105
 TABLE 57 CANADA: LIQUID BIOPSY MARKET SIZE, BY PRODUCT, 2014–2021 (USD MILLION) 106
 TABLE 58 CANADA: LIQUID BIOPSY MARKET SIZE, BY CIRCULATING BIOMARKER,
 2014–2021 (USD MILLION) 107
 TABLE 59 CANADA: LIQUID BIOPSY MARKET SIZE, BY END USER, 2014–2021 (USD MILLION) 107
 TABLE 60 EUROPE: LIQUID BIOPSY MARKET SIZE, BY TYPE OF CANCER,
 2014–2021 (USD MILLION) 110
 TABLE 61 EUROPE: LIQUID BIOPSY MARKET SIZE, BY PRODUCT, 2014–2021 (USD MILLION) 110
 TABLE 62 EUROPE: LIQUID BIOPSY MARKET SIZE, BY CIRCULATING BIOMARKER,
 2014–2021 (USD MILLION) 111
 TABLE 63 EUROPE: LIQUID BIOPSY MARKET SIZE, BY END USER, 2014–2021 (USD MILLION) 112
 TABLE 64 ASIA-PACIFIC: LIQUID BIOPSY MARKET SIZE, BY TYPE OF CANCER,
 2014–2021 (USD MILLION) 115
 TABLE 65 ASIA-PACIFIC: LIQUID BIOPSY MARKET SIZE, BY PRODUCT,
 2014–2021 (USD MILLION) 116
 TABLE 66 ASIA-PACIFIC: LIQUID BIOPSY MARKET SIZE, BY CIRCULATING BIOMARKER,
 2014–2021 (USD MILLION) 117
 TABLE 67 ASIA-PACIFIC: LIQUID BIOPSY MARKET SIZE, BY END USER,
 2014–2021 (USD MILLION) 117
 TABLE 68 ROW: LIQUID BIOPSY MARKET SIZE, BY TYPE OF CANCER,
 2014–2021 (USD MILLION) 118
 TABLE 69 ROW: LIQUID BIOPSY MARKET SIZE, BY PRODUCT, 2014–2021 (USD MILLION) 119
 TABLE 70 ROW: LIQUID BIOPSY MARKET SIZE, BY CIRCULATING BIOMARKER,
 2014–2021 (USD MILLION) 120
 TABLE 71 ROW: LIQUID BIOPSY MARKET SIZE, BY END USER, 2014–2021 (USD MILLION) 120
 TABLE 72 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS, 2013–2016 124
 TABLE 73 NEW PRODUCT LAUNCHES, 2013–2016 125
 TABLE 74 ACQUISITIONS, 2013-2016 126
 TABLE 75 OTHER DEVELOPMENTS, 2013–2016 127


List Of Figures

 FIGURE 1 RESEARCH DESIGN 18
 FIGURE 2 EPIDEMIOLOGY MODEL 20
 FIGURE 3 MARKET SIZE ESTIMATION AND DATA TRIANGULATION 21
 FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 22
 FIGURE 5 MARKET DATA TRIANGULATION METHODOLOGY 23
 FIGURE 6 LIQUID BIOPSY MARKET SIZE, BY PRODUCT, 2016 VS. 2021 (USD MILLION) 27
 FIGURE 7 LIQUID BIOPSY MARKET SIZE, BY CANCER TYPE, 2016 VS. 2021 (USD MILLION) 27
 FIGURE 8 LIQUID BIOPSY MARKET SIZE, BY CIRCULATING BIOMARKER,
 2016 VS. 2021 (USD MILLION) 28
 FIGURE 9 LIQUID BIOPSY MARKET SIZE, BY END USER, 2016 VS. 2021 (USD MILLION) 29
 FIGURE 10 GEOGRAPHICAL SNAPSHOT OF THE LIQUID BIOPSY MARKET, 2016 30
 FIGURE 11 INCREASING NUMBER OF NEW CANCER CASES—PRIMARY GROWTH DRIVER FOR THE LIQUID BIOPSY MARKET 31
 FIGURE 12 CIRCULATING TUMOR CELLS SEGMENT TO ACCOUNT FOR THE LARGEST MARKET SHARE IN 2016 32
 FIGURE 13 REFERENCE LABORATORIES SEGMENT WILL CONTINUE TO DOMINATE THE LIQUID BIOPSY MARKET IN 2021 33
 FIGURE 14 REAGENTS SEGMENT DOMINATES THE LIQUID BIOPSY MARKET IN 2016 33
 FIGURE 15 CIRCULATING TUMOR CELLS SEGMENT ACCOUNTS FOR THE LARGEST MARKET SHARE IN 2016 34
 FIGURE 16 ASIA-PACIFIC TO REGISTER THE HIGHEST GROWTH RATE IN THE FORECAST PERIOD 35
 FIGURE 17 LIQUID BIOPSY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, CHALLENGES 37
 FIGURE 18 INCREASING NUMBER OF NEW CANCER CASES WORLDWIDE (2012-2020) 38
 FIGURE 19 COST COMPARISON BETWEEN LIQUID AND INCISIONAL BIOPSY 39
 FIGURE 20 RELATIONSHIP BETWEEN LIQUID BIOPSY SENSITIVITY AND NUMBER OF METASTATIC SITES 43
 FIGURE 21 DISCOVERY AND DEVELOPMENT OF MEDICAL DEVICES 46
 FIGURE 22 NEW CANCER CASES, BY COUNTRY (2012) 55
 FIGURE 23 NEW CANCER CASES, BY COUNTRY (2020) 55
 FIGURE 24 NEW CANCER CASES WORLDWIDE (2012 VS. 2015 VS. 2020) 56
 FIGURE 25 LUNG CANCER WILL CONTINUE TO ACCOUNT FOR THE LARGEST SHARE IN 2021 56
 FIGURE 26 NORTH AMERICA WILL CONTINUE TO DOMINATE THE LIQUID BIOPSY MARKET FOR LUNG CANCER BY 2021 58
 FIGURE 27 ASIA-PACIFIC OFFERS LUCRATIVE OPPORTUNITIES IN THE LIQUID BIOPSY MARKET FOR BREAST CANCER 60
 FIGURE 28 NORTH AMERICA WILL CONTINUE TO LEAD THE LIQUID BIOPSY MARKET FOR COLORECTAL CANCER IN 2021 62
 FIGURE 29 NORTH AMERICA WILL CONTINUE TO LEAD THE LIQUID BIOPSY MARKET FOR PROSTATE CANCER IN 2021 63
 FIGURE 30 NORTH AMERICA WILL CONTINUE TO LEAD THE LIQUID BIOPSY MARKET FOR LIVER CANCER IN 2021 65
 FIGURE 31 NEW CASES OF OTHER CANCER TYPES WORLDWIDE (2012—2020) 66
 FIGURE 32 NORTH AMERICA WILL CONTINUE TO LEAD THE OTHER CANCERS MARKET IN 2021 67
 FIGURE 33 CIRCULATING TUMOR CELLS TO ACCOUNT FOR THE LARGEST SHARE OF THE LIQUID BIOPSY MARKET 70
 FIGURE 34 NORTH AMERICA WILL CONTINUE TO ACCOUNT FOR LARGEST MARKET SHARE
 IN 2021 71
 FIGURE 35 NORTH AMERICA TO ACCOUNT FOR THE LARGEST MARKET SHARE IN 2021 73
 FIGURE 36 NORTH AMERICA WILL CONTINUE TO ACCOUNT FOR LARGEST MARKET SHARE
 IN 2021 75
 FIGURE 37 NORTH AMERICA TO DOMINATE THE MARKET FOR OTHER BIOMARKERS 77
 FIGURE 38 THE REAGENTS PRODUCT SEGMENT WILL CONTINUE TO ACCOUNT FOR THE LARGEST SHARE OF THE MARKET IN THE FORECAST PERIOD 80
 FIGURE 39 NORTH AMERICA WILL CONTINUE TO DOMINATE THE MARKET FOR LIQUID BIOPSY REAGENTS DURING THE FORECAST PERIOD 81
 FIGURE 40 ASIA-PACIFIC TO WITNESS HIGHEST GROWTH IN THE LIQUID BIOPSY INSTRUMENTS MARKET BY 2021 83
 FIGURE 41 NORTH AMERICA WILL CONTINUE TO DOMINATE THE MARKET FOR LIQUID BIOPSY SERVICES & SOFTWARE IN 2021 85
 FIGURE 42 REFERENCE LABORATORIES SEGMENT WILL CONTINUE TO DOMINATE THE MARKET 88
 FIGURE 43 ASIA-PACIFIC REFERENCE LABORATORIES END-USER SEGMENT TO SHOW HIGHEST GROWTH 89
 FIGURE 44 NORTH AMERICA, THE LARGEST SEGMENT IN THE HOSPITAL / PHYSICIAN LABORATORIES MARKET 90
 FIGURE 45 NORTH AMERICA WILL CONTINUE TO DOMINATE THE LIQUID BIOPSY MARKET FOR ACADEMIC AND RESEARCH CENTERS 92
 FIGURE 46 ASIA-PACIFIC TO GROW AT THE HIGHEST RATE IN THE LIQUID BIOPSY MARKET FOR OTHER END USERS 93
 FIGURE 47 NORTH AMERICA TO ACCOUNT FOR THE LARGEST SHARE OF THE LIQUID BIOPSY MARKET IN 2016 96
 FIGURE 48 NORTH AMERICA LIQUID BIOPSY MARKET SNAPSHOT 97
 FIGURE 49 NORTH AMERICAN LUNG CANCER SEGMENT TO ACCOUNT FOR THE LARGEST SHARE OF THE LIQUID BIOPSY MARKET IN 2016 98
 FIGURE 50 CIRCULATING TUMOR CELLS SEGMENT EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICAN LIQUID BIOPSY MARKET IN 2016 100
 FIGURE 51 LUNG CANCER TO DOMINATE U.S. LIQUID BIOPSY MARKET, BY CANCER TYPE,
 TILL 2021 102
 FIGURE 52 REFERENCE LABORATORIES END-USER SEGMENT TO ACCOUNT FOR THE LARGEST SHARE OF THE U.S. LIQUID BIOPSY MARKET IN 2016 104
 FIGURE 53 LUNG CANCER WILL CONTINUE TO DOMINATE THE CANADIAN LIQUID BIOPSY MARKET TILL 2021 105
 FIGURE 54 REAGENTS ACCOUNT FOR THE LARGEST SHARE OF THE CANADIAN LIQUID BIOPSY MARKET IN 2016 106
 FIGURE 55 EUROPE: CANCER FREQUENCY, BY COUNTRY, 2012 (PER 100,000 POPULATION) 108
 FIGURE 56 MEDICAL INSURANCE COVERAGE OF MAJOR EUROPEAN COUNTRIES, 2013 109
 FIGURE 57 LUNG CANCER SEGMENT TO ACCOUNT FOR THE LARGEST SHARE OF THE LIQUID BIOPSY MARKET IN 2016 109
 FIGURE 58 REFERENCE LABORATORIES, THE LARGEST END-USER SEGMENT IN THE EUROPEAN MARKET 111
 FIGURE 59 ASIA-PACIFIC LIQUID BIOPSY MARKET SNAPSHOT 114
 FIGURE 60 LUNG CANCER IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC LIQUID BIOPSY MARKET IN 2016 115
 FIGURE 61 CIRCULATING TUMOR CELLS SEGMENT TO DOMINATE ASIA-PACIFIC LIQUID BIOPSY MARKET IN 2016 116
 FIGURE 62 LUNG CANCER WILL DOMINATE THE ROW LIQUID BIOPSY MARKET TILL 2021 118
 FIGURE 63 REAGENTS PRODUCT SEGMENT TO COMMAND LARGEST SHARE OF THE ROW LIQUID BIOPSY MARKET 119
 FIGURE 64 COMPANIES ADOPTED AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS AS THEIR KEY GROWTH STRATEGY OVER THE LAST FOUR YEARS (2013-2016) 122
 FIGURE 65 AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS - KEY GROWTH STRATEGIES ADOPTED BY PLAYERS IN THE LIQUID BIOPSY MARKET 123
 FIGURE 66 GEOGRAPHIC REVENUE MIX OF TOP FOUR MARKET PLAYERS 128
 FIGURE 67 BIOCEPT, INC.: COMPANY SNAPSHOT 129
 FIGURE 68 QIAGEN: COMPANY SNAPSHOT 132
 FIGURE 69 COMPANY SNAPSHOT: F. HOFFMANN-LA ROCHE AG 135
 FIGURE 70 COMPANY SNAPSHOT: BIO-RAD LABORATORIES INC. 137
 FIGURE 71 MYRIAD GENETICS: COMPANY SNAPSHOT 139
 FIGURE 72 JOHNSON & JOHNSON: COMPANY SNAPSHOT 142
 FIGURE 73 TRAVOGENE INC.: COMPANY SNAPSHOT 144
 FIGURE 74 MDX HEALTH: COMPANY SNAPSHOT 148


Genaera Liquidating Trust Company Profile- Outlook, Business Segments, Competitors, Goods and Services, SWOT and Financial Analysis

Genaera Liquidating Trust Company Profile is a complete analysis of the companys operations, strategies, outlook and historic performance. The research work analyzes key strategies in current market conditions, SWOT profile,

USD 200View Report

PEDEC – Natural Gas Liquids 3200 Extraction Plant – Iran - Construction Project Profile

Synopsis PEDEC Natural Gas Liquids 3200 Extraction Plant Iran contains information on the scope of the project including project overview and location. The profile also details project ownership and

USD 75View Report

Global Compressed Carbon Dioxide Gas & Liquid Carbon Dioxide Market Research Report 2016

Notes:Production, means the output of Compressed Carbon Dioxide Gas & Liquid Carbon DioxideRevenue, means the sales value of Compressed Carbon Dioxide Gas & Liquid Carbon DioxideThis report studies Compressed Carbon

USD 2900View Report

Europe Liquid Biopsy Products Market Report 2016

Notes:Sales, means the sales volume of Liquid Biopsy ProductsRevenue, means the sales value of Liquid Biopsy ProductsThis report studies sales (consumption) of Liquid Biopsy Products in Europe market, especially in

USD 3900View Report

United States Liquid Biopsy Products Market Report 2016

Notes:Sales, means the sales volume of Liquid Biopsy ProductsRevenue, means the sales value of Liquid Biopsy ProductsThis report studies sales (consumption) of Liquid Biopsy Products in United States market, focuses

USD 3800View Report

Global Liquid Biopsy Products Market Professional Survey Report 2016

Notes:Production, means the output of Liquid Biopsy ProductsRevenue, means the sales value of Liquid Biopsy ProductsThis report studies Liquid Biopsy Products in Global market, especially in North America, Europe, China,

USD 3500View Report

Fill The Form For Sample Request
Name*
Email*
Mobile No.*
LandLine No.
If you want to purchase particular section from this report then kindly contact us at contact@aarkstore.com.

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

Discount on PDF and Enterprise Wide Licence reports
  • PDF $ 5650    $ 5650
  • Multi User Licence $ 6650    $ 6650
  • Corporate Licence $ 8150    $ 8150
  • Enterprise Wide Licence $ 10000    $ 10000
$ 5650

Reports Details

Published Date : Jul 2016
No. of Pages :161
Country :Global
Category :Healthcare
Publisher :MarketsandMarkets
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment